Abstract 352P
Background
Breast cancer (BC) and its treatment could disturb the reproductive system. We identified reproductive system disorders following chemotherapy in patients with BC and the determinant factors.
Methods
One hundred and twelve married female patients with BC who underwent first chemotherapy between 2018 and 2020 in Dr. Sardjito Hospital, Yogyakarta were recruited. Socio-demographic and clinical data were collected at baseline. After each chemotherapy session, the patients were interviewed about symptoms of reproductive system disorder (irregular menstruation, vaginal dryness, decreased libido, dyspareunia, delayed orgasm and anorgasmia) and other symptoms (fatigue, anorexia, nausea and anxiety). We used a questionnaire based on the CTCAE version 4. Data of symptoms were collected until patients received at least 3 treatment cycles. Chi square and Fisher’s exact tests were used to analyze any association among variables.
Results
The most common symptoms were vaginal dryness (41.1%) followed by decreased libido (39.3%). In the subgroup analysis, the most common symptom among 44 pre-menopause women was irregular menstruation (84.1%). Vaginal dryness occurred more in cases with anthracycline-based regimen (p=0.036) and with anxiety (p=0.019), compared to their counterparts. Decreased libido presented more in cases with younger age (p=0.037) and positive ER status (p=0.009). Irregular menstruation, dyspareunia, delayed orgasm, and anorgasmia did not correlate with any of the determinant factors.
Conclusions
Reproductive system disorders occurred very frequently in the local BC patients after receiving chemotherapy. Influencing factors included anthracycline-based regimen, anxiety, age, and estrogen receptor status.
Clinical trial identification
Editorial acknowledgement
Erik Christopher Hookom, BA, M.Ed, TEFL Office of Research and Publication, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada.
Legal entity responsible for the study
The authors.
Funding
The Indonesian Ministry of Research, Technology, and Higher Education; Public Funding, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
193P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Exploratory survival analyses by change in post treatment CA 19-9
Presenter: Andrew Dean
Session: e-Poster Display Session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session